Healthcare Business Review: Teva and Mylan CHARGED By EU, Novartis WINS EU Approval

Here are Monday’s top stories:

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA), France’s Servier, Mylan Inc. (NASDAQ:MYL), plus three other firms, have been charged by European Union competition regulators with preventing generic perindopril medicines from entering the market. Perindopril is indicated in the treatment of hypertension, and also to help patients avoid problems subsequent to heart attacks and procedures.

Don’t Miss: Becton Dickinson Third Quarter Earnings Sneak Peek.

Shares of Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) lost a third of their value Monday on news that Pfizer, Inc. (NYSE:PFE) had terminated the license to three development-stage drugs that use Acura’s tech, on Friday.

Regulators in the European Union have approved Novartis AG’s (NYSE:NVS) Afinitor drug for the treatment of women suffering from a certain type of breast cancer. The medication was already okayed by the FDA for breast cancer, and authorized for four other types of the disease. Analyst Martin Voegtli at Kepler Capital Markets predicts that Afinitor is set to be a blockbuster by 2013.

Don’t Miss: Clorox Fourth Quarter Earnings Sneak Peek.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.